Synthesis: First-line metastatic TNBC therapy

Evidence grades (GRADE-adapted): A high — multiple well-conducted RCTs or systematic reviews converge. B moderate — single pivotal RCT or consistent observational evidence. C limited — single observational study, mechanistic, or expert consensus. D preclinical / hypothesis-generating.

The biomarker-stratified decision frame

Before 2018, first-line metastatic TNBC was a single default: single-agent cytotoxic chemotherapy, with regimen choice driven by prior exposure and toxicity profile. Two pivotal-trial readouts split this into a three-path decision tree:

• If PD-L1 CPS ≥ 10 (22C3 assay): pembrolizumab + chemotherapy, per KEYNOTE-355^[1]A.
• If germline BRCA1 or BRCA2 mutation (irrespective of PD-L1): PARP inhibitor monotherapy is an option, per OlympiAD (olaparib)^[2] or EMBRACA (talazoparib)^[3]A.
• Otherwise: single-agent chemotherapy, with sequencing across multiple lines as the cancer progresses^[4]B.

In contemporary US/EU practice, approximately 35–40% of metastatic TNBC patients qualify for the pembrolizumab path (CPS ≥ 10), roughly 10–15% qualify for the PARP path (germline BRCA1/2), with some overlap between the two; the remaining ~50% receive chemotherapy alone first-line^[5]B. The chemotherapy-alone subgroup is the largest and the one with the least progress over the past decade — an active investigational area.

Path 1: KEYNOTE-355 — pembrolizumab + chemotherapy in PD-L1+ disease

Cortes and colleagues randomized 847 patients with previously untreated locally recurrent inoperable or metastatic TNBC 2:1 to pembrolizumab + investigator's-choice chemotherapy (nab-paclitaxel, paclitaxel, or gemcitabine + carboplatin) vs placebo + the same chemotherapy backbone^[1]. PD-L1 was measured prospectively with the 22C3 assay; pre-specified analyses tested benefit at CPS ≥ 1, CPS ≥ 10, and the ITT population in hierarchical order.

The headline efficacy results, from the initial 2020 Lancet publication^[1]:

• CPS ≥ 10 subgroup PFS: median 9.7 vs 5.6 months, HR 0.65 (95% CI 0.49–0.86; p=0.0012)
• CPS ≥ 1 subgroup PFS: median 7.6 vs 5.6 months, HR 0.74 (95% CI 0.61–0.90; p=0.0014)
• ITT PFS: median 7.5 vs 5.6 months, HR 0.82 — numerical benefit; the statistical hierarchy precluded formal significance testing

The 2022 NEJM OS update^[6]A formalized the survival benefit in the CPS ≥ 10 subgroup: median OS 23.0 vs 16.1 months (HR 0.73; 95% CI 0.55–0.95; p=0.0185). The CPS ≥ 1 and ITT analyses did not reach statistical significance for OS at the same time point, consistent with a dose-response relationship between PD-L1 expression and IO benefit.

Regulatory consequence: the FDA approved pembrolizumab + chemotherapy for first-line metastatic TNBC with CPS ≥ 10 (22C3) in November 2020. EMA followed in 2021. NCCN guidelines list this as the preferred first-line regimen for the PD-L1+ subgroup.

Practical implementation notes:

• The chemotherapy backbone is investigator's choice; cross-arm data don't favor one backbone over the others in this trial. In US practice nab-paclitaxel and gemcitabine + carboplatin are the most common.
• The CPS scoring threshold is specific to the 22C3 assay; results from SP142 (IC scoring) do not interconvert — see the PD-L1 testing synthesis for the assay-heterogeneity story.
• Immune-related adverse event monitoring is required throughout treatment per the ASCO irAE management guideline^[7]A.

Path 2: PARP inhibitors in germline-BRCA-mutated disease

Two pivotal trials established PARP inhibitor monotherapy as a first-line metastatic option for patients with germline BRCA1 or BRCA2 pathogenic variants. Both enrolled HER2-negative metastatic breast cancer, with a majority TNBC subgroup.

OlympiAD (olaparib)

Robson and colleagues randomized 302 patients with germline-BRCA-mutated HER2-negative metastatic breast cancer 2:1 to olaparib 300 mg twice daily vs single-agent chemotherapy of physician's choice (capecitabine, eribulin, or vinorelbine)^[2]. The trial enrolled both HR+ and HR− patients; ~50% were TNBC.

• Primary endpoint PFS: 7.0 vs 4.2 months (HR 0.58; 95% CI 0.43–0.80; p<0.001)
• Response rate: 59.9% vs 28.8%
• OS in the overall trial population did not reach significance at median follow-up; subset analyses suggested benefit concentrated in earlier-line patients

EMBRACA (talazoparib)

Litton and colleagues randomized 431 patients with germline-BRCA-mutated HER2-negative metastatic breast cancer 2:1 to talazoparib 1 mg daily vs single-agent physician's-choice chemotherapy^[3]. Similar trial design, similar enrollment mix (~45% TNBC).

• Primary endpoint PFS: 8.6 vs 5.6 months (HR 0.54; 95% CI 0.41–0.71; p<0.001)
• Response rate: 62.6% vs 27.2%
• OS HR 0.85 (not significant at primary analysis); long-term follow-up has not changed the conclusion

Both trials supported regulatory approval (olaparib in 2018; talazoparib in 2018). Head-to-head data do not exist; cross-trial comparison favors talazoparib on PFS by a small margin, but with a different toxicity profile (more myelosuppression with talazoparib; more nausea with olaparib). Choice between the two is typically based on toxicity considerations and prior exposure.

PARP sequencing relative to chemotherapy

An open clinical question in 2020 was whether PARP inhibition should precede or follow chemotherapy in first-line metastatic care. Current consensus, informed by both trials' early-line stratification:

• Pace of disease matters. Patients with rapidly progressing visceral crisis benefit from chemotherapy first (faster onset of response). Indolent or oligometastatic disease can start with PARP inhibitor.
• Sequence does not appear to alter overall outcomes substantially, though PARP-naive patients have higher response rates than those who have already received platinum-containing chemotherapy^[8]B.
• Combination of PARP + chemotherapy first-line has been tested (BROCADE3 and others) without compelling benefit over sequential single agents.

For patients who are both germline BRCA-positive and PD-L1 CPS ≥ 10, the trials don't directly compare pembrolizumab + chemo vs PARP-inhibitor monotherapy. Clinical decision-making is individualized; the recent inclination has been to favor pembrolizumab + chemo first-line if both options are available, with PARP held for later progression in the BRCA-mutated population.

Path 3: Chemotherapy alone — the dominant biomarker-negative subgroup

Approximately half of metastatic TNBC patients are PD-L1 CPS < 10 AND germline BRCA-wildtype. For these patients, first-line is single-agent chemotherapy, with the agent chosen for tolerability and prior-exposure considerations rather than for maximum cell-kill efficacy. Standard options:

• Taxanes (paclitaxel, nab-paclitaxel, docetaxel) — first-line workhorse when not used in the adjuvant setting. Nab-paclitaxel preferred for solvent-allergy or hypersensitivity history.
• Anti-metabolites (capecitabine, gemcitabine) — oral capecitabine convenient; gemcitabine preferred for visceral disease.
• Platinums (carboplatin, cisplatin) — meaningful single-agent activity in TNBC; reasonable first-line in patients without prior platinum exposure^[9]A.
• Combinations (carboplatin + gemcitabine; carboplatin + paclitaxel) — higher response rate at the cost of more toxicity; reasonable for visceral-crisis presentation.

The TNT trial (Tutt 2018)^[9] specifically compared carboplatin vs docetaxel as first-line metastatic for unselected TNBC: PFS was similar overall, but a pre-specified subgroup analysis suggested carboplatin advantage in the germline-BRCA subset. This finding has informed contemporary preference for platinum in BRCA-mutated TNBC even when PARP inhibitor is being held for later use.

Median PFS on first-line single-agent chemotherapy in unselected metastatic TNBC is approximately 4–6 months; median OS is 12–18 months^[10]B. These numbers have not changed substantially since the early 2010s — the chemotherapy-alone subgroup is where the field most needs new agents.

Evidence table — pivotal first-line metastatic trials

Biomarker testing requirements at first-line presentation

A clean first-line decision requires four test results before initial therapy is chosen. NCCN and ESMO guidelines both recommend completing all four before non-chemotherapy paths are excluded:

1. HER2 IHC (with ISH reflex on 2+) — confirms HER2-low vs HER2-zero (for later-line trastuzumab deruxtecan eligibility; see IHC synthesis).
2. PD-L1 CPS (22C3 assay) — gates pembrolizumab path.
3. Germline genetic testing (BRCA1, BRCA2, PALB2 at minimum) — gates PARP path. Per NCCN, all TNBC patients should have germline testing regardless of age or family history^[11]A.
4. Comprehensive tumor profiling (often via commercial NGS panel) — for trial eligibility and uncommon actionable mutations (PIK3CA, AKT1, NTRK fusions, MSI/MMR).

In contemporary practice these four tests are often ordered at metastatic diagnosis as a single batch, with results back within 2–3 weeks. Initiating chemotherapy without these results is permissible when disease pace requires urgent treatment, but biomarker-driven path-switches in cycles 2–3 should be anticipated.

Open questions and active investigation

• What works for biomarker-negative TNBC first-line? The largest patient subgroup has had the least progress. Active investigational classes for biomarker-negative first-line include: novel ADCs in earlier lines (datopotamab deruxtecan via TROPION-Breast trials; patritumab deruxtecan); novel IO combinations beyond pembrolizumab + chemo (TIGIT inhibitors, LAG-3 inhibitors); AR antagonists for the LAR molecular subtype (see subtype synthesis).
• Sequencing pembrolizumab and PARP in dual-positive patients. Patients who are both CPS ≥ 10 and germline BRCA+ have no head-to-head first-line guidance. Optimal sequencing is unresolved; trials are ongoing.
• Earlier sacituzumab govitecan or trastuzumab deruxtecan. Both ADCs are currently established post-progression. Moving them to first-line in biomarker-stratified subgroups is the focus of multiple ongoing trials (ASCENT-03, ASCENT-04, DESTINY-Breast15 and others).
• Atezolizumab's return. After atezolizumab's TNBC indication was withdrawn following IMpassion131's failure, the question of whether atezolizumab is biologically inferior to pembrolizumab vs whether the IMpassion131 result was a chemotherapy-backbone artefact remains unresolved. A head-to-head trial is unlikely to be funded now that atezolizumab is no longer marketed for this indication.
• Beyond germline BRCA for PARP. Somatic BRCA mutations, PALB2 mutations, and broader HRD signatures have been tested as PARP-inhibitor predictors with mixed results. Talazoparib in the TALA-PALB2 expansion (Gruber 2022) showed activity in PALB2-mutated patients. Whether broader HRD score-based selection works in TNBC remains under investigation.
• Optimal duration of pembrolizumab in responders. KEYNOTE-355's protocol allowed pembrolizumab indefinitely until progression or toxicity. Whether shorter fixed-duration treatment (12 or 24 months) is non-inferior is being tested; no head-to-head data yet.

For the metastatic-after-first-line ADC era, see Sacituzumab govitecan (ASCENT) and Trastuzumab deruxtecan in HER2-low (DESTINY-Breast04). For deeper PARP-inhibitor biology, see PARP inhibitors in BRCA-mutated metastatic TNBC. For the PD-L1 assay heterogeneity behind the CPS ≥ 10 threshold, see PD-L1 testing and assay heterogeneity. For the patient-layer companion, see Treatment options.

References

Each citation links to the original publication via DOI. The same records are searchable in the evidence library by title or DOI.

1. Cortes J, Cescon DW, Rugo HS, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355). Lancet. 2020;396(10265):1817–1828. doi:10.1016/S0140-6736(20)32531-9. ↩
2. Robson M, Im SA, Senkus E, et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation (OlympiAD). N Engl J Med. 2017;377(6):523–533. doi:10.1056/NEJMoa1706450. ↩
3. Litton JK, Rugo HS, Ettl J, et al. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation (EMBRACA). N Engl J Med. 2018;379(8):753–763. doi:10.1056/NEJMoa1802905. ↩
4. Cardoso F, Paluch-Shimon S, Schumacher-Wulf E, et al. 6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7). Breast. 2024;76:103756. doi:10.1016/j.breast.2024.103756. ↩
5. Howard FM, Olopade OI. Epidemiology of Triple-Negative Breast Cancer: A Review. Cancer J. 2021;27(1):8–16. doi:10.1097/PPO.0000000000000500. ↩
6. Cortes J, Rugo HS, Cescon DW, et al. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2022;387(3):217–226. doi:10.1056/NEJMoa2202809. ↩
7. Schneider BJ, Naidoo J, Santomasso BD, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol. 2021;39(36):4073–4126. doi:10.1200/JCO.21.01440. ↩
8. Tutt ANJ, Tovey H, Cheang MCU, et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT trial. Nat Med. 2018;24(5):628–637. doi:10.1038/s41591-018-0009-7. ↩
9. Tutt A, Tovey H, Cheang MC, et al. The TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer. Cancer Res. 2015;75(9 Suppl):S3-01. doi:10.1158/1538-7445.SABCS14-S3-01. ↩
10. Bianchini G, De Angelis C, Licata L, Gianni L. Triple-negative breast cancer: an evolving moving target. Nat Rev Clin Oncol. 2022;19(2):91–113. doi:10.1038/s41571-021-00565-2. ↩
11. Daly MB, Pal T, Berry MP, et al. NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021. J Natl Compr Canc Netw. 2021;19(1):77–102. doi:10.6004/jnccn.2021.0001. ↩

Last reviewed: 2026-06-04. Researcher-layer synthesis page. Evidence grades follow the GRADE-adapted rubric defined at the top of this page.